Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.42 |
| ▸ | GGH | Q92820 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.40 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.39 |
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4437670 | 0.91 | KMT2A (0.46) | NAALAD2C3AR1CA2CA1KDM4E | |
| SCHEMBL4992916 | 0.88 | C3AR1 (0.44) | NAALAD2C3AR1KDM4EHPGD | |
| SCHEMBL4430852 | 0.87 | C3AR1 (0.46) | NAALAD2C3AR1 | |
| SCHEMBL5134378 | 0.86 | C3AR1 (0.47) | C3AR1PYGL | |
| SCHEMBL4433904 | 0.86 | C3AR1 (0.47) | C3AR1PYGL | |
| SCHEMBL27772204 | 0.86 | KDM4E (0.43) | C3AR1KDM4EHPGD | |
| Bromide SCHEMBL4992858 | 0.85 | C3AR1 (0.46) | C3AR1PYGL | |
| Bromide SCHEMBL4986289 | 0.85 | C3AR1 (0.46) | C3AR1PYGL | |
| SCHEMBL4439606 | 0.85 | C3AR1 (0.46) | C3AR1CA2CA1FOLH1PYGL | |
| SCHEMBL4428267 | 0.85 | NPSR1 (0.38) | NAALAD2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101611008-A | C3A receptor modulators and methods of use thereof | ENCYSIVE PHARMACEUTICALS INC (US) | 2009-12-23 | — | — | CN | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | NAALAD2 3124/4885GAA 4404/4885C3AR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.